

**Anti-pig Antibodies in Swine Veterinarian Serum: Implications for Clinical Xenotransplantation.**

Byrne Guerard W<sup>1,2</sup> and McGregor Christopher GA<sup>1,2</sup>

**Affiliations:**

1. University of Minnesota, Twin Cities  
Department of Surgery  
Experimental Surgical Services  
Minneapolis, MN
2. University College London  
Institute of Cardiovascular Sciences  
London WC1E 6BT

Address Correspondence to  
Guerard W. Byrne  
University of Minnesota, Twin Cities  
Department of Surgery  
Minneapolis, MN  
byrne413@umn.edu

**Financial Support**

This work was supported by Experimental Surgical Services, University of Minnesota and FIOS Therapeutic Inc.

**Conflict of Interest**

Dr. Byrne has no conflicts to declare. Dr. McGregor is founder of FIOS Therapeutics.

**Keywords**

Xenotransplantation, barcoding, antibody mediated rejection

**Abbreviations**

AASP	American Association of Swine Practitioners
AMR	Antibody mediated rejection
APC	Allophycocyanin
BSA	bovine serum albumin
CSFE	carboxyfluorescein diacetate, succinimidyl ester
eFluor450	organic cell proliferation dye eFluor450
Gal	the galactose a 1,3 galactose glycan encoded by the GGTA-1 gene
HEK	human embryonic kidney cells
HLA	human leukocyte antigen
Neu5Gc	N-glycolylneuraminic acid modified glycans dependent on a functional CMAH gene
NHP	nonhuman primates
PBS	phosphate buffered saline
SDa	GalNAc $\beta$ 1,4 (Neu5Ac $\alpha$ 2,3) Gal glycan encoded by the B4GALNT2 gene
SLA	swine leukocyte antigen
TKO	triple knockout pigs not producing the Gal, SDa or Neu5Gc glycans

**Abstract**

Recent clinical xenotransplantation and human decedent studies demonstrate that clinical hyperacute rejection of genetically engineered porcine organs can be reliably avoided but that antibody mediated rejection continues to limit graft survival. We previously identified porcine glycans and proteins which are immunogenic after cardiac xenotransplantation in nonhuman primates, but the clinical immune response to antigens present in glycan depleted triple knockout (TKO) donor pigs is poorly understood. In this study we use fluorescence barcoded HEK cells and HEK cell lines expressing porcine glycans (Gal and SDa) or proteins (CD9, CD46, CD59, PROCR and ANXA2) to screen antibody reactivity in human serum from 160 swine veterinarians, a serum source with potential occupational immune challenge from porcine tissues and pathogens. High levels of anti-Gal IgM were present in all samples and lower levels of anti-SDa IgM were present in 41% of samples. IgM binding to porcine proteins, primarily CD9 and CD46, previously identified as immunogenic in pig to non-human primate cardiac xenograft recipients, was detected in 28 of the 160 swine veterinarian samples. These results suggest that barcoded HEK cell lines expressing porcine protein antigens can be useful for screening human patient serum. A comprehensive analysis of sera from clinical xenotransplant recipients to define a panel of commonly immunogenic porcine antigens will likely be necessary to establish an array of porcine non-Gal antigens for effective monitoring of patient immune responses and allow earlier therapies to reverse antibody mediated rejection.

## Introduction

Xenotransplantation is dominated by antibody mediated rejection (AMR) characterized by complement dependent cytotoxicity, antibody-dependent cell cytotoxicity and chronic endothelial cell activation [1, 2]. The bulk of human antibody to porcine tissue is directed to the alpha-Gal antigen (Gal) which is the target of discordant complement dependent hyperacute rejection of pig organs in nonhuman primates (NHPs) [3]. With the development and testing of pigs mutated in the porcine GGTA-1 gene required for Gal synthesis (Gal-KO), it became evident that additional antibodies to non-Gal glycan and protein antigens were present and could contribute to xenograft rejection [4]. The non-Gal glycans include N-glycolylneuraminic acid (Neu5Gc) modified glycans and the SID blood group antigen SDa (GalNAc  $\beta$ 1,4 (Neu5Ac  $\alpha$ 2,3) Gal) [5, 6]. Anti-Neu5Gc antibodies, not present in NHP recipients, have long been recognized in humans as a contributory cause of serum sickness after dosing of patients with animal serum [7]. The role of the SID blood group antigen SDa was identified by screening a porcine endothelial cell expression library with sensitized serum IgG from NHPs after cardiac xenotransplantation [6]. This screen identified the porcine B4GALNT2 gene, the enzyme required for synthesis of the SDa glycan, as the source of a new previously unrecognized immunogenic porcine glycan [8]. SID is a polyagglutinable blood group because most individuals have low levels of anti-SDa IgM which agglutinates red blood cells with high SDa levels [5, 9, 10]. Cells from pigs engineered with mutations to eliminate expression of the Gal, Neu5Gc and SDa glycans, triple knockout pigs (TKO), show greatly reduced human antibody binding, with about 30% of patient samples showing no apparent reactivity [11].

Far less is known about the clinical potential for antibodies induced to porcine protein antigens.

Antibodies to human leukocyte antigens (HLA) have been shown to cross react with certain subsets of swine leukocyte antigen (SLA) [12, 13]. This suggests that a preformed and potentially induced immune response to swine SLA could contribute to clinical xenograft rejection. Others, using proteomic analysis have reported a broader range of human antibody specificities [14]. Consistent with this observation residual human IgM reactivity to TKO pig cells has been described from a variety of human serum sources [15].

The two recent first clinical cardiac xenotransplants implanting TKO 10-gene modified organs both failed with evidence of apparent AMR, highlighting the critical importance of identifying clinical antibody responses to non-Gal antigens [16]. Early analysis of non-Gal immune responses in NHPs suggested a pan-pig response to porcine proteins [17]. Proteomic studies suggested a range of potential target proteins with some evidence of immunodominant antigens [18, 19]. Using a porcine endothelial cell expression library, we identified a series of pig endothelial cell membrane protein antigens which are immunogenic in NHPs after cardiac xenotransplantation [6]. In the current study, we examined serum samples from swine veterinarians, with potential occupational exposure to swine antigens, to test human antibody reactivity to specific immunogenic porcine glycans and proteins expressed on human embryonic kidney cells (HEK).

## Materials and Methods

### Swine Practitioner Serum

Serum samples collected from swine veterinarians attending the 1999 Annual Meeting of the American Association of Swine Practitioners (AASP) were previously described [20]. For this study an anonymized set of 160 AASP serum samples were tested for reactivity to porcine antigens expressed on human embryonic kidney 293 cells (HEK).

### Cell Culture

HEK cells and stably transfected HEK cells expressing the porcine GGTA-1 (HEK-Gal), B4GALNT2 (HEK-SDa), CD9 (HEK-CD9), CD46 (HEK-CD46), CD59 (HEK-CD59), PROC (HEK-PROCR) and ANXA2 (HEK-ANXA2) have been previously described [6, 21, 22]. All HEK cell lines were grown in DMEM media supplemented with 10% fetal calf serum, 1% glutamine, nonessential amino acids, and 110 mg/L sodium pyruvate. Cells for flow cytometry were collected at 80% confluence from T-75 flasks using 0.25% trypsin (Gibco, Fisher Scientific Waltham, MA).

### Cell Barcoding and Cell Staining

HEK and HEK cells expressing porcine antigens were labelled with combinations of the vital dyes carboxyfluorescein diacetate, succinimidyl ester (CFSE) (eBioscience CFSE, Fisher Scientific Waltham, MA) and eFluor450 (eBioscience proliferation dye eFluor450, Fisher Scientific Waltham, MA) as described [23]. HEK cell lines were labelled separately with combinations of CFSE, at final concentrations of 0, 0.01 or 0.15  $\mu\text{M}$ , and eFluor450, at final concentrations of 0, 0.2 and 3.0  $\mu\text{M}$ , producing 9 distinct fluorescence groups (**Figure 1A**). For labelling cells were collected from tissue culture plates, washed and resuspended in 0.5 ml of phosphate buffered saline (PBS) at  $4 \times 10^6/\text{ml}$ . Vital dyes diluted in PBS were distributed into 9 separate tubes containing: 1 (0.0  $\mu\text{M}$  CFSE, 0.0  $\mu\text{M}$  eFL450), 2 (0.0  $\mu\text{M}$  CFSE, 0.2  $\mu\text{M}$  eFL450), 3 (0  $\mu\text{M}$  CFSE, 3.0  $\mu\text{M}$  eFL450), 4 (0.01  $\mu\text{M}$  CFSE, 0.0  $\mu\text{M}$  eFL450), 5 (0.01  $\mu\text{M}$  CFSE, 0.2  $\mu\text{M}$  eFL450), 6 (0.01  $\mu\text{M}$  CFSE, 3.0  $\mu\text{M}$  eFL450), 7 (0.15  $\mu\text{M}$  CFSE, 0.0  $\mu\text{M}$  eFL450), 8 (0.15  $\mu\text{M}$  CFSE, 0.2  $\mu\text{M}$  eFL450), 9 (0.15  $\mu\text{M}$  CFSE, 3.0  $\mu\text{M}$  eFL450). To each tube PBS and 0.5 ml of cells ( $2 \times 10^6$ ) were added to a final volume of 1ml. Cells were incubated at 37° C for 8 minutes to label and then quenched with PBS containing 1% BSA (PBS/BSA). The cells were pelleted and resuspended in complete DMEM media and incubated at 37° C for 10 minutes prior to washing twice with PBS/BSA. Labelled cells were resuspended in 1 ml of PBS/BSA and equal volumes of each labelled population were combined for staining by human serum.

### Flow Cytometry

Flow cytometry measurements were made using a BD Biosciences (San Jose) FACSCanto II flow cytometer equipped with 405 nm, 488 nm and 633 nm lasers. All 9 CFSE and eFluor450 labelled barcoded HEK cell populations (180,000 cells) were mixed and incubated with human serum (diluted

1:10) at 4° C for 45 minutes, washed with PBS/BSA and stained with an APC-conjugated mouse anti-Human IgM (BD Pharmingen). Antibody binding to specific target porcine antigens was measured by gating on each individual barcoded cell population. For each analysis two HEK control populations were present and a secondary only negative control was used. Positive controls included staining with purified human anti-Gal antibody and with serum from highly sensitized NHP cardiac xenotransplantation recipients [18, 24]. The results were analyzed with FlowJo version 10.9.0. A median fluorescence index (MFI) was calculated by dividing the sample Median fluorescence value by the average median fluorescence for all HEK control cells.

#### Homology Comparisons

All homology comparisons were performed using reference porcine and human protein sequences from the NCBI nucleotide database. Homology and matrix identity was determined using the Uniprot alignment program Clustal Omega 2.1. Supplemental files show the detailed porcine and human homology comparisons for CD46 isoforms (Supplement\_1) and for the other protein antigens (Supplement\_2).

#### Statistics

Background staining of HEK control cells was determined as the average median HEK staining of all HEK samples processed that day. The minimal cutoff for positive reactivity to HEK cells expressing porcine glycans/proteins was set to the average HEK stain for that day plus 3 standard deviation. Serum samples with strong anti-protein reactivity had median antibody reactivity in excess of 5SD higher than the HEK control. Quantitative values are presented as means  $\pm$  standard deviations.

## Results

We adapted a high throughput cell barcoding scheme to detect human antibody binding to control HEK cells and to HEK cells expressing xeno-specific glycans (Gal or SDa) or porcine proteins (CD9, CD46, CD59, PROCR, ANXA2) from 160 AASP veterinarian serum samples (**Figure 1A-D**). Each serum sample simultaneously stained 9 distinct CFSE and eFluor450 labelled barcoded cell populations consisting of 2 control HEK cell populations and 7 additional HEK cell population each expressing one porcine glycan or protein antigen. It became evident early on that there was no IgG reactivity to porcine proteins so only IgM results are presented.

### Glycan Reactivity

All 160 serum samples showed positive IgM binding to HEK-Gal cells which was minimally 3 standard deviations (SD) higher than the average median IgM binding to control HEK cells (Figure 1C and 2A). For HEK-Gal cells the averaged median fluorescence index was  $40.5 \pm 31.5$ , indicating an average 40-fold higher level of antibody binding than to the HEK controls. Over half of the samples (89 of 160, 57%) exhibited exclusively anti-Gal IgM binding and no other anti-porcine reactivity. Anti-SDa IgM was detected in 65 serum samples (41%) with an average MFI of  $3.9 \pm 2.3$ , approximately 10-fold lower than anti-Gal reactivity (**Figure 1D and 2B**). All of the SDa reactive sera were also positive for Gal with 43 of 65 sera exclusively binding to HEK-Gal and HEK-SDa with no reactivity to any of the protein expressing cells. A total of 132 AASP serum samples (82.5%) showed IgM binding to Gal or Gal and SDa with no evident anti-protein reactivity.

### Porcine Protein reactivity

There were 28 samples which exhibited IgM binding to at least 1 protein antigen (**Figure 2C and Figure 3A-C**). Most of these sera (19 of 28), which always showed anti-Gal and or anti-SDa activity, reacted with only 1 protein (**Table 1**). Reactivity to HEK-CD46 was most common (n=24) followed by reactivity to HEK-CD9 (n=8) and HEK-CD59 (n=6). In addition to anti-glycan binding, 7 serum samples bound to 2 proteins, reacting with CD46 and CD9 in 4 samples and CD46 and CD59 in the other 3 samples. One serum sample reacted with three protein antigen (CD46, CD9 and CD59) and one sample bound all 5 HEK cells expressing porcine proteins. Of these 28 serum samples 14 had anti-protein reactivity, for at least 1 protein antigen, which exceeded 5 standard deviations above the control HEK levels (**Figure 2C**).

## Discussion

Based on successful preclinical studies in NHPs, xenotransplantation has made significant clinical advances with two recent orthotopic clinical heart transplants with promising outcomes performed at the University of Maryland using TKO 10-gene-edited pig hearts [16, 25-27]. There have also been a series of renal and cardiac transplants with various donor genetics into decedent patients [28-30]. The apparent AMR at 35 and 47 days in the TKO 10-gene-edited heart xenograft recipients and similar AMR at 33 days in a single 2 month renal decedent study (Robert Montgomery, personal communications) suggests that antibody responses continue to contribute to clinical xenograft rejection. Although human anti-HLA antibody is known to cross react with some porcine SLA proteins, the polymorphic status of MHC antigens is not unique to xenotransplantation, suggesting that an induced immune response to a range of endothelial cell proteins is likely to develop.

In this report we examine serum samples from 160 swine veterinarians using a novel high throughput barcoded screening assay. This serum was collected from swine veterinarians and represents a population of veterinarians at high risk for occupational exposure to pig antigens and pathogens. Previous analysis of this serum collection showed that these swine veterinarians had an increased risk of occupational exposure and increased potential risk of zoonotic HEV infection [20]. In the current study we found that all samples contained high levels of anti-Gal IgM with about 40% of the samples showing both anti-Gal and anti-SDa IgM reactivity with no binding to pig protein antigens. The anti-SDa IgM was about 10-fold lower than anti-Gal IgM which is consistent with what is known about the SID blood group [5, 9, 10]. In 28 serum samples we detected evidence of IgM binding to one or more of the porcine proteins, predominantly CD46 and CD9 (**Table 1**). The level of antibody binding to porcine proteins was comparable, though much less frequent, to IgM binding to SDa (**Figure 2B and C**). In 14-of-28 serum samples, anti-protein binding was easily detected exceeding 5 standard deviations above average IgM binding to control HEK cells (**Figure 2C**). These results suggest that some degree of occupational immune challenge occurred in a minority of swine veterinarians leading to easily detected IgM reactivity to porcine proteins.

All porcine proteins in this study show some level of amino acid polymorphism compared to their human homologues (**Table 2, Supplement\_1 and Supplement\_2**). Anti-protein reactivity in the AASP serum samples was primarily directed at porcine CD46 and CD9. CD46 is a type I transmembrane protein with a small carboxy-terminal hydrophobic transmembrane domain and a short cytoplasmic region. The remainder of the protein forms an extensive extracellular domain composed of four short consensus repeats (SCRs). The more distal SCRs 1 - 3 are highly polymorphic with slightly better conservation present in SCR 4. Alternative splicing creates multiple isoforms of CD46 in both pigs and humans, however, there remains significant polymorphism in all isoforms with the amino acid identity ranging from 44 - 48% (**Supplement\_1**). The relatively high levels of polymorphism across the extracellular region of CD46 would contribute to the immunogenicity of this protein. CD9 has 4 transmembrane domains and

two extracellular loops. The overall amino acid identity between pig and human is high (90.18%) with perfect conservation across the 4 transmembrane domains. The major polymorphisms occur in the second extracellular loop, a region of 85 amino acids with only 75.9% amino acid identity [31]. Similar levels of polymorphism are present in the extracellular domains of GPI-linked CD59 and in the type I membrane protein PROCR [32]. Porcine annexinA2 shows minimal polymorphism and was poorly detected in this study or in previous studies of serum from NHPs [6].

There are several limitations in this study which limit our conclusions. First we have no insight into the route, nature, timing, frequency or level of occupation exposure that the swine veterinarians may have experienced. As such we cannot comment on the quantitative level of immunogenicity for any of the antigens we have studied. The absence of IgG reactivity to any of the proteins studied may suggest that occupation exposure is far less intense than immunization or xenotransplantation. Each of the HEK cell lines is unique and there will be variations in the level of antigen expression from one line to the other. This variation may have quantitative effects on the sensitivity and level of antibody binding, making comparisons between antigens difficult. Despite these limitations, it is clear that substantial antibody binding to several porcine proteins was present in a notable number of serum samples, suggesting that these, and potentially other porcine proteins, may be clinically immunogenic after xenotransplantation.

## **Conclusions**

Human antibody responses to immune challenge from vaccination and allotransplant are affected by a large number of factors which, in addition to immunosuppression, may also impact the development of AMR in clinical xenotransplantation [33, 34]. Here we show that a number of swine veterinarians with potential occupational exposure to pig tissues and pathogens have IgM which binds to specific pig proteins which were previously identified as immunogenic after preclinical cardiac xenotransplantation. While the HEK cell lines used in this study may be useful for screening patient serum, this was not a comprehensive survey of pig protein immunogenicity and it is plausible that proteins identified here and other porcine proteins, including SLA antigens, may be immunogenic in clinical xenotransplantation. There are now a very limited set of clinical samples from cardiac xenotransplantation recipients and decedent studies. Careful analysis of these sera will be valuable to identify a set of commonly immunogenic non-Gal antigens. A panel of such antigens, displayed on HEK cells, as single antigen beads or other display formats, would be a foundation for monitoring patient immune responses. In the case of complement or thrombolytic regulators it may be advantageous in xenotransplantation to substitute the human gene for a porcine gene which is found to be chronically immunogenic. This genetic engineering approach and more effective immunosuppression, rejection monitoring and therapy or even B-cell tolerance may be necessary for long-term clinical xenograft survival.

## References

1. McGregor, C.G.A. and G.W. Byrne, *Porcine to Human Heart Transplantation: Is Clinical Application Now Appropriate?* J Immunol Res, 2017.
2. Mohiuddin, M.M., B. Reichart, G.W. Byrne and C.G. McGregor, *Current status of pig heart xenotransplantation.* Int J Surg, 2015. **23**(Pt B): p. 234-239.
3. Platt, J.L., S.S. Lin and C.G. McGregor, *Acute vascular rejection.* Xenotransplantation, 1998. **5**(3): p. 169-175.
4. Kolber-Simonds, D., L. Lai, S.R. Watt, M. Denaro, S. Arn, M.L. Augenstein, et al., *Production of alpha-1,3-galactosyltransferase null pigs by means of nuclear transfer with fibroblasts bearing loss of heterozygosity mutations.* Proc Natl Acad Sci U S A, 2004. **101**(19): p. 7335-40.
5. Stenfelt, L., A. Hellberg and M.L. Olsson, *SID: a new carbohydrate blood group system based on a well-characterized but still mysterious antigen of great pathophysiologic interest.* Immunohematology, 2023. **39**(1): p. 1-10.
6. Byrne, G.W., P.G. Stalboerger, Z. Du, T.R. Davis and C.G. McGregor, *Identification of new carbohydrate and membrane protein antigens in cardiac xenotransplantation.* Transplantation, 2011. **91**(3): p. 287-92.
7. Dhar, C., A. Sasmal and A. Varki, *From "Serum Sickness" to "Xenosialitis": Past, Present, and Future Significance of the Non-human Sialic Acid Neu5Gc.* Front Immunol, 2019. **10**: p. 807.
8. Byrne, G., S. Ahmad-Villiers, Z. Du and C. McGregor, *B4GALNT2 and xenotransplantation: A newly appreciated xenogeneic antigen.* Xenotransplantation, 2018. **25**(5): p. e12394.
9. Duca, M., N. Malagolini and F. Dall'Olio, *The story of the Sd(a) antigen and of its cognate enzyme B4GALNT2: What is new?* Glycoconj J, 2023. **40**(1): p. 123-133.
10. Bird, G.W. and J. Wingham, *Cad(super Sda) in a British family with eastern connections: a note on the specificity of the Dolichos biflorus lectin.* J Immunogenet, 1976. **3**(5): p. 297-302.
11. Martens, G.R., L.M. Reyes, P. Li, J.R. Butler, J.M. Ladowski, J.L. Estrada, et al., *Humoral Reactivity of Renal Transplant-Waitlisted Patients to Cells From GGTA1/CMAH/B4GalNT2, and SLA Class I Knockout Pigs.* Transplantation, 2017. **101**(4): p. e86-e92.
12. Martens, G.R., J.M. Ladowski, J. Estrada, Z.Y. Wang, L.M. Reyes, J. Easlick, et al., *HLA Class I-sensitized Renal Transplant Patients Have Antibody Binding to SLA Class I Epitopes.* Transplantation, 2019. **103**(8): p. 1620-1629.
13. Ladowski, J.M., L.M. Reyes, G.R. Martens, J.R. Butler, Z.Y. Wang, D.E. Eckhoff, et al., *Swine Leukocyte Antigen Class II Is a Xenoantigen.* Transplantation, 2018. **102**(2): p. 249-254.
14. Burlak, C., Z.Y. Wang, R.K. Chihara, A.J. Lutz, Y. Wang, J.L. Estrada, et al., *Identification of human preformed antibody targets in GTKO pigs.* Xenotransplantation, 2012. **19**(2): p. 92-101.
15. He, S., T. Li, H. Feng, J. Du, D.K.C. Cooper, H. Hara, et al., *Incidence of serum antibodies to xenoantigens on triple-knockout pig cells in different human groups.* Xenotransplantation, 2023: p. e12818.
16. Griffith, B.P., C.E. Goerlich, A.K. Singh, M. Rothblatt, C.L. Lau, A. Shah, et al., *Genetically Modified Porcine-to-Human Cardiac Xenotransplantation.* N Engl J Med, 2022. **387**(1): p. 35-44.
17. Buhler, L., Y. Xu, W. Li, A. Zhu and D.K. Cooper, *An investigation of the specificity of induced anti-pig antibodies in baboons.* Xenotransplantation, 2003. **10**(1): p. 88-93.
18. Byrne, G.W., P.G. Stalboerger, E. Davila, C.J. Heppelmann, M.H. Gazi, H.C. McGregor, et al., *Proteomic identification of non-Gal antibody targets after pig-to-primate cardiac xenotransplantation.* Xenotransplantation, 2008. **15**(4): p. 268-76.
19. Gollackner, B., I. Qawi, S. Daniel, E. Kaczmarek, D.K. Cooper and S.C. Robson, *Potential target molecules on pig kidneys recognized by naive and elicited baboon antibodies.* Xenotransplantation, 2004. **11**(4): p. 380-1.

20. Meng, X.J., B. Wiseman, F. Elvinger, D.K. Guenette, T.E. Toth, R.E. Engle, et al., *Prevalence of antibodies to hepatitis E virus in veterinarians working with swine and in normal blood donors in the United States and other countries*. J Clin Microbiol, 2002. **40**: p. 117-122.
21. Byrne, G.W., Z. Du, P. Stalboerger, H. Kogelberg and C.G. McGregor, *Cloning and expression of porcine beta1,4 N-acetylgalactosaminyl transferase encoding a new xenoreactive antigen*. Xenotransplantation, 2014. **21**(6): p. 543-554.
22. McGregor, C.G., G.W. Byrne, Z. Fan, C.J. Davies and I.A. Polejaeva, *Genetically Engineered Sheep: a New Paradigm for Future Preclinical Testing of Biological Heart Valves*. J Thorac Cardiovasc Surg, 2023. **in press**.
23. Lu, M., B.M. Chan, P.W. Schow, W.S. Chang and C.T. King, *High-throughput screening of hybridoma supernatants using multiplexed fluorescent cell barcoding on live cells*. J Immunol Methods, 2017. **451**: p. 20-27.
24. McGregor, C.G., A. Carpentier, N. Lila, J.S. Logan and G.W. Byrne, *Cardiac xenotransplantation technology provides materials for improved bioprosthetic heart valves*. J Thorac Cardiovasc Surg, 2011. **141**(1): p. 269-275.
25. Goerlich, C.E., B. Griffith, P. Hanna, S.N. Hong, D. Ayares, A.K. Singh, et al., *The growth of xenotransplanted hearts can be reduced with growth hormone receptor knockout pig donors*. J Thorac Cardiovasc Surg, 2023. **165**(2): p. e69-e81.
26. Langin, M., T. Mayr, B. Reichart, S. Michel, S. Buchholz, S. Guethoff, et al., *Consistent success in life-supporting porcine cardiac xenotransplantation*. Nature, 2018. **564**(7736): p. 430-433.
27. Mohiuddin, M.M., A.K. Singh, L. Scobie, C.E. Goerlich, A. Grazioli, K. Saharia, et al., *Graft dysfunction in compassionate use of genetically engineered pig-to-human cardiac xenotransplantation: a case report*. Lancet, 2023. **402**(10399): p. 397-410.
28. Porrett, P.M., B.J. Orandi, V. Kumar, J. Hou, D. Anderson, A. Cozette Killian, et al., *First clinical-grade porcine kidney xenotransplant using a human decedent model*. Am J Transplant, 2022. **22**(4): p. 1037-1053.
29. Loupy, A., V. Goutaudier, A. Giarraputo, F. Mezine, E. Morgand, B. Robin, et al., *Immune response after pig-to-human kidney xenotransplantation: a multimodal phenotyping study*. Lancet, 2023. **402**(10408): p. 1158-1169.
30. Moazami, N., J.M. Stern, K. Khalil, J.I. Kim, N. Narula, M. Mangiola, et al., *Pig-to-human heart xenotransplantation in two recently deceased human recipients*. Nat Med, 2023. **29**(8): p. 1989-1997.
31. Yubero, N., A. Jimenez-Marin, M. Yerle, L. Morera, M.J. Barbancho, D. Llanes, et al., *Molecular cloning, expression pattern and chromosomal mapping of pig CD9 antigen*. Cytogenet Genome Res, 2003. **101**(2): p. 143-6.
32. Fukudome, K. and C.T. Esmon, *Molecular cloning and expression of murine and bovine endothelial cell protein C/activated protein C receptor (EPCR). The structural and functional conservation in human, bovine, and murine EPCR*. J Biol Chem, 1995. **270**(10): p. 5571-7.
33. Zimmermann, P. and N. Curtis, *Factors That Influence the Immune Response to Vaccination*. Clin Microbiol Rev, 2019. **32**(2).
34. Heeger, P.S., M.C. Haro and S. Jordan, *Translating B cell immunology to the treatment of antibody-mediated allograft rejection*. Nat Rev Nephrol, 2024.

**Tables**

Table 1. Human IgM Reactivity to Porcine Proteins

Proteins detected (N)	Serum (N)	CD46	CD9	CD59	PROCR	ANXA2
1	19	15	3	1	0	0
2	7	7	4	3	0	0
3	1	1	0	1	1	0
4	0	0	0	0	0	0
5	1	1	1	1	1	1

Table 2. Protein Homology

Protein	amino acids*	% amino acid identity**
CD46	384	46.0
CD9	226	90.2
CD59	123	47.5
PROCR	242	70.6
ANXA2	339	97.9

\* Values are the number of amino acids in the porcine protein. \*\* CD46 has multiple isoforms. The values for amino acids and % amino acid identity are representative.

### Figure Legends

**Figure 1.** Barcoding of the HEK cell series and screening for human anti-pig antibody reactivity. **A.** Cells, 1; HEK control, 2; HEK-Gal, 3; HEK-SDa, 4; HEK-CD9, 5; HEK-CD59, 6; HEK-CD46, 7; HEK-PROCR, 8; HEK-ANXA2, and 9; HEK control are stained with different levels of the vital dyes CSFE (x-axis) and eFluor450 (y-axis) as described in the Materials and Methods. **B.** The barcoded population of HEK cells are combined, stained with veterinarian serum and resolved into 9 distinct cell populations based on fluorescence of the vital dyes. Antibody binding to individual antigens is evident by gating on each individual cell population **C.** All serum samples had anti-Gal IgM with 89 samples (56%) showing only anti-Gal IgM reactivity and no reactivity to other porcine antigens. **D.** Anti-SDa and anti-Gal IgM with no binding to any protein antigens was present in 43 samples (27%).

**Figure 2.** **A** summary of AASP swine veterinarian serum IgM binding to glycan (**A and B**) and protein antigens (**C**). **A.** Shows anti-Gal IgM reactivity for 160 AASP swine serum samples. All samples had anti-Gal reactivity. **B.** Shows IgM binding to SDa for 65 AASP serum samples with antibody binding greater than 3 standard deviations above background. **C.** Shows IgM binding to protein antigens for 28 AASP serum samples with antibody binding greater than 3 standard deviations above background. Note the change in y-axis scale between panel **A** and panels **B and C**. Black filled circles in panels **A - C** are IgM binding to control HEK cells. The dotted line in **B and C** represents 5 standard deviations above the average MFI of all HEK control cells.

**Figure 3.** AASP swine veterinarian serum showing anti-porcine protein IgM binding. **A.** Serum showing IgM binding to Gal, SDa and CD46. **B.** Serum showing IgM binding to Gal, SDa and CD9. **C.** Serum showing IgM binding to Gal, SDa, CD9, CD59, CD46, PROCR and ANXA2. All anti-protein reactivity in panels **A-C** exceeded 5 standard deviations above the HEK background, except for the anti-ANXA2 activity in panel **C**

Figure 1.




Figure 2.





Figure 3.



Byrne\_Supplement\_1

Percent Identity Matrix - created by Clustal2.1  
#Comparing pig and human isoforms of CD46  
Amino acid identity ranges from 44.35 - 48.57%

1: FIGXP_020957856.1	100.0	98.35	95.00	99.17	45.01	46.11	44.69	44.35	45.07	45.40	45.56	44.92	44.92	44.66	45.38	46.04
2: FIGNP_999053.1	98.35	100.0	98.62	99.17	47.29	48.57	47.04	46.65	47.46	47.87	47.32	46.63	46.63	46.31	47.09	47.87
3: FIGXP_020957857.1	95.00	98.62	100.0	99.45	45.69	46.83	47.47	47.09	47.88	48.27	45.43	44.79	44.79	44.54	45.25	45.91
4: FIGXP_020957858.1	99.17	99.17	99.45	100.0	47.29	48.57	47.04	46.65	47.46	47.87	47.32	46.63	46.63	46.31	47.09	47.87
5: HUNP_758868.1	45.01	47.29	45.69	47.29	100.0	100.0	92.05	90.73	91.01	92.38	93.68	92.40	92.40	93.66	93.94	93.41
6: HUNP_758860.1	46.11	48.57	46.83	48.57	100.0	100.0	94.72	92.96	92.96	94.58	95.87	94.56	94.56	95.87	95.87	95.69
7: HUNP_758863.1	44.69	47.04	47.47	47.04	92.05	94.72	100.0	97.29	97.81	100.0	95.80	93.31	93.31	94.75	95.26	95.69
8: HUXP_054192621.1	44.35	46.65	47.09	46.65	90.73	92.96	97.29	100.0	99.73	100.0	94.12	94.49	94.49	94.44	93.94	95.69
9: HUNP_758866.1	45.07	47.46	47.88	47.46	91.01	92.96	97.81	99.73	100.0	100.0	94.12	95.79	95.79	93.94	94.21	95.69
10: HUNP_758871.1	45.40	47.87	48.27	47.87	92.38	94.58	100.0	100.0	100.0	100.0	95.69	95.69	95.69	95.69	95.69	95.69
11: HUXP_054192624.1	45.56	47.32	45.43	47.32	93.68	95.87	95.80	94.12	94.12	95.69	100.0	98.87	98.87	100.0	100.0	100.0
12: HUXP_047276857.1	44.92	46.63	44.79	46.63	92.40	94.56	93.31	94.49	95.79	95.69	98.87	100.0	100.0	97.52	98.88	100.0
13: HUMNP_758865.1	44.92	46.63	44.79	46.63	92.40	94.56	93.31	94.49	95.79	95.69	98.87	100.0	100.0	97.52	98.88	100.0
14: HUXP_054192620.1	44.66	46.31	44.54	46.31	93.66	95.87	94.75	94.44	93.94	95.69	100.0	97.52	97.52	100.00	99.73	100.0
15: HUXP_047276850.1	45.38	47.09	45.25	47.09	93.94	95.87	95.26	93.94	94.21	95.69	100.0	98.88	98.88	99.73	100.00	100.0
16: HUNP_758867.1	46.04	47.87	45.91	47.87	93.41	95.69	95.69	95.69	95.69	95.69	100.0	100.00	100.0	100.0	100.0	100.0

CLUSTAL O(1.2.4) multiple sequence alignment

```

PIGXP_020957856.1    MMAFCALRKALPCRPNPFSSRCFVEILWVSLALVFLLPMSDACDEPPKFESMRPQVL-    59
PIGNP_999053.1      MMAFCALRKALPCRPNPFSSRCFVEILWVSLALVFLLPMSDACDEPPKFESMRPQFL-    59
PIGXP_020957857.1    MMAFCALRKALPCRPNPFSSRCFVEILWVSLALVFLLPMSDACDEPPKFESMRPQVL-    59
PIGXP_020957858.1    MMAFCALRKALPCRPNPFSSRCFVEILWVSLALVFLLPMSDACDEPPKFESMRPQVL-    59
HUNP_758868.1        -----MEPPGRRECFPFSWRFPGLLLA--AMVLLLYSFSDACDEPPTFEAMELIGKP    50
HUNP_758860.1        -----MEPPGRRECFPFSWRFPGLLLA--AMVLLLYSFSDACDEPPTFEAMELIGKP    50
HUNP_758863.1        -----MEPPGRRECFPFSWRFPGLLLA--AMVLLLYSFSDACDEPPTFEAMELIGKP    50
HUXP_054192621.1     -----MEPPGRRECFPFSWRFPGLLLA--AMVLLLYSFSDACDEPPTFEAMELIGKP    50
HUNP_758866.1        -----MEPPGRRECFPFSWRFPGLLLA--AMVLLLYSFSDACDEPPTFEAMELIGKP    50
HUNP_758871.1        -----MEPPGRRECFPFSWRFPGLLLA--AMVLLLYSFSDACDEPPTFEAMELIGKP    50
HUXP_054192624.1     -----MEPPGRRECFPFSWRFPGLLLA--AMVLLLYSFSDACDEPPTFEAMELIGKP    50
HUXP_047276857.1     -----MEPPGRRECFPFSWRFPGLLLA--AMVLLLYSFSDACDEPPTFEAMELIGKP    50
HUMNP_758865.1       -----MEPPGRRECFPFSWRFPGLLLA--AMVLLLYSFSDACDEPPTFEAMELIGKP    50
HUXP_054192620.1     -----MEPPGRRECFPFSWRFPGLLLA--AMVLLLYSFSDACDEPPTFEAMELIGKP    50
HUXP_047276850.1     -----MEPPGRRECFPFSWRFPGLLLA--AMVLLLYSFSDACDEPPTFEAMELIGKP    50
HUNP_758867.1        -----MEPPGRRECFPFSWRFPGLLLA--AMVLLLYSFSDACDEPPTFEAMELIGKP    50
                    * * * * * * * : * . * : * * * * * * * * * * * * * * * * * * * *

```

```

PIGXP_020957856.1    NTTYRPGDRVEYECRPGFQPMVPALPTSSVCQDDNTWSPLQ-EACRRKACSNLDPDLNGQ    118
PIGNP_999053.1      NTTYRPGDRVEYECRPGFQPMVPALPTSSVCQDDNTWSPLQ-EACRRKACSNLDPDLNGQ    118
PIGXP_020957857.1    NTTYRPGDRVEYECRPGFQPMVPALPTSSVCQDDNTWSPLQ-EACRRKACSNLDPDLNGQ    118
PIGXP_020957858.1    NTTYRPGDRVEYECRPGFQPMVPALPTSSVCQDDNTWSPLQ-EACRRKACSNLDPDLNGQ    118
HUNP_758868.1        KPYEIGERVVDYKCKKGYFY-IPPLATHTICDRNHTWLPVSDDACYRETCPYIRDPLNGQ    109
HUNP_758860.1        KPYEIGERVVDYKCKKGYFY-IPPLATHTICDRNHTWLPVSDDACYRETCPYIRDPLNGQ    109
HUNP_758863.1        KPYEIGERVVDYKCKKGYFY-IPPLATHTICDRNHTWLPVSDDACYRETCPYIRDPLNGQ    109
HUXP_054192621.1     KPYEIGERVVDYKCKKGYFY-IPPLATHTICDRNHTWLPVSDDACYRETCPYIRDPLNGQ    109
HUNP_758866.1        KPYEIGERVVDYKCKKGYFY-IPPLATHTICDRNHTWLPVSDDACYRETCPYIRDPLNGQ    109
HUNP_758871.1        KPYEIGERVVDYKCKKGYFY-IPPLATHTICDRNHTWLPVSDDACYRETCPYIRDPLNGQ    109
HUXP_054192624.1     KPYEIGERVVDYKCKKGYFY-IPPLATHTICDRNHTWLPVSDDACYRETCPYIRDPLNGQ    109
HUXP_047276857.1     KPYEIGERVVDYKCKKGYFY-IPPLATHTICDRNHTWLPVSDDACYRETCPYIRDPLNGQ    109
HUMNP_758865.1       KPYEIGERVVDYKCKKGYFY-IPPLATHTICDRNHTWLPVSDDACYRETCPYIRDPLNGQ    109
HUXP_054192620.1     KPYEIGERVVDYKCKKGYFY-IPPLATHTICDRNHTWLPVSDDACYRETCPYIRDPLNGQ    109
HUXP_047276850.1     KPYEIGERVVDYKCKKGYFY-IPPLATHTICDRNHTWLPVSDDACYRETCPYIRDPLNGQ    109
HUNP_758867.1        KPYEIGERVVDYKCKKGYFY-IPPLATHTICDRNHTWLPVSDDACYRETCPYIRDPLNGQ    109
                    : * . * : * * * * * * * : * * * * * * * * * * * * * * * * * * * *

```

```

PIGXP_020957856.1    VSYPNGDTLFGSKAQFTCNTGFYIIIGAETVYCQVSGNVMAWSEPSPLCEKILCKPPGEIP    178
PIGNP_999053.1      VSYPNGDMLFGSKAQFTCNTGFYIIIGAETVYCQVSGNVMAWSEPSPLCEKILCKPPGEIP    178
PIGXP_020957857.1    VSYPNGDTLFGSKAQFTCNTGFYIIIGAETVYCQVSGNVMAWSEPSPLCEKILCKPPGEIP    178
PIGXP_020957858.1    VSYPNGDTLFGSKAQFTCNTGFYIIIGAETVYCQVSGNVMAWSEPSPLCEKILCKPPGEIP    178
HUNP_758868.1        AVPANGTYEFGYQMHFICNEGYYLIGEEILYCELGKSVAIWSGKPPICEKVLCTPPPKIK    169
HUNP_758860.1        AVPANGTYEFGYQMHFICNEGYYLIGEEILYCELGKSVAIWSGKPPICEKVLCTPPPKIK    169
HUNP_758863.1        AVPANGTYEFGYQMHFICNEGYYLIGEEILYCELGKSVAIWSGKPPICEKVLCTPPPKIK    169
HUXP_054192621.1     AVPANGTYEFGYQMHFICNEGYYLIGEEILYCELGKSVAIWSGKPPICEKVLCTPPPKIK    169
HUNP_758866.1        AVPANGTYEFGYQMHFICNEGYYLIGEEILYCELGKSVAIWSGKPPICEKVLCTPPPKIK    169
HUNP_758871.1        AVPANGTYEFGYQMHFICNEGYYLIGEEILYCELGKSVAIWSGKPPICEKVLCTPPPKIK    169
HUXP_054192624.1     AVPANGTYEFGYQMHFICNEGYYLIGEEILYCELGKSVAIWSGKPPICEKVLCTPPPKIK    169
HUXP_047276857.1     AVPANGTYEFGYQMHFICNEGYYLIGEEILYCELGKSVAIWSGKPPICEKVLCTPPPKIK    169
HUMNP_758865.1       AVPANGTYEFGYQMHFICNEGYYLIGEEILYCELGKSVAIWSGKPPICEKVLCTPPPKIK    169
HUXP_054192620.1     AVPANGTYEFGYQMHFICNEGYYLIGEEILYCELGKSVAIWSGKPPICEKVLCTPPPKIK    169
HUXP_047276850.1     AVPANGTYEFGYQMHFICNEGYYLIGEEILYCELGKSVAIWSGKPPICEKVLCTPPPKIK    169
HUNP_758867.1        AVPANGTYEFGYQMHFICNEGYYLIGEEILYCELGKSVAIWSGKPPICEKVLCTPPPKIK    169
                    . ** ** * : * * * * * * * * * * * * * * * * * * * * * * * * * *

```

PIGXP_020957856.1	NGKYTNSHKDVFEYNEVVITYSCLSSSTGPDFSLVGESSLFCIGKDEWSSDPPECKVVKCP	238
PIGNP_999053.1	NGKYTNSHKDVFEYNEVVITYSCLSSSTGPDFSLVGESSLFCIGKDEWSSDPPECKVVKCP	238
PIGXP_020957857.1	NGKYTNSHKDVFEYNEVVITYSCLSSSTGPDFSLVGESSLFCIGKDEWSSDPPECKVVKCP	238
PIGXP_020957858.1	NGKYTNSHKDVFEYNEVVITYSCLSSSTGPDFSLVGESSLFCIGKDEWSSDPPECKVVKCP	238
HUNP_758868.1	NGKHTFSEVEVFEYLDAVTYSCDPAPGPDPPFLIGESTIYCGDNSVWSRAAPECKVVKCR	229
HUNP_758860.1	NGKHTFSEVEVFEYLDAVTYSCDPAPGPDPPFLIGESTIYCGDNSVWSRAAPECKVVKCR	229
HUNP_758863.1	NGKHTFSEVEVFEYLDAVTYSCDPAPGPDPPFLIGESTIYCGDNSVWSRAAPECKVVKCR	229
HUXP_054192621.1	NGKHTFSEVEVFEYLDAVTYSCDPAPGPDPPFLIGESTIYCGDNSVWSRAAPECKVVKCR	229
HUNP_758866.1	NGKHTFSEVEVFEYLDAVTYSCDPAPGPDPPFLIGESTIYCGDNSVWSRAAPECKVVKCR	229
HUNP_758871.1	NGKHTFSEVEVFEYLDAVTYSCDPAPGPDPPFLIGESTIYCGDNSVWSRAAPECKVVKCR	229
HUXP_054192624.1	NGKHTFSEVEVFEYLDAVTYSCDPAPGPDPPFLIGESTIYCGDNSVWSRAAPECKVVKCR	229
HUXP_047276857.1	NGKHTFSEVEVFEYLDAVTYSCDPAPGPDPPFLIGESTIYCGDNSVWSRAAPECKVVKCR	229
HUMNP_758865.1	NGKHTFSEVEVFEYLDAVTYSCDPAPGPDPPFLIGESTIYCGDNSVWSRAAPECKVVKCR	229
HUXP_054192620.1	NGKHTFSEVEVFEYLDAVTYSCDPAPGPDPPFLIGESTIYCGDNSVWSRAAPECKVVKCR	229
HUXP_047276850.1	NGKHTFSEVEVFEYLDAVTYSCDPAPGPDPPFLIGESTIYCGDNSVWSRAAPECKVVKCR	229
HUNP_758867.1	NGKHTFSEVEVFEYLDAVTYSCDPAPGPDPPFLIGESTIYCGDNSVWSRAAPECKVVKCR	229

\*\*\*:\* \*. :\*\*\*\* :.\*\*\*\*\* : \*\*\* \*\*:\*\*\*\*::\* :. \*\* \*\*\*\*\*

PIGXP\_020957856.1 YPVVNGEIVSGFGSKFYYKAEVVFKNAGFTLHGRDTIVCGANSTWEPEMPQCICKDSKP 298  
PIGNP\_999053.1 YPVVNGEIVSGFGSKFYYKAEVVFKNAGFTLHGRDTIVCGANSTWEPEMPQCICKDSKP 298  
PIGXP\_020957857.1 YPVVNGEIVSGFGSKFYYKAEVVFKNAGFTLHGRDTIVCGANSTWEPEMPQCICKDSKP 298  
PIGXP\_020957858.1 YPVVNGEIVSGFGSKFYYKAEVVFKNAGFTLHGRDTIVCGANSTWEPEMPQCICKDSKP 298  
HUNP\_758868.1 FPPVENGKQISGFGKKFYYKATVMFECDKGFYLDGSDTIVCDSNSTWDPVVPKCLKVVS-- 287  
HUNP\_758860.1 FPPVENGKQISGFGKKFYYKATVMFECDKGFYLDGSDTIVCDSNSTWDPVVPKCLK---- 285  
HUNP\_758863.1 FPPVENGKQISGFGKKFYYKATVMFECDKGFYLDGSDTIVCDSNSTWDPVVPKCLKGPRP 289  
HUXP\_054192621.1 FPPVENGKQISGFGKKFYYKATVMFECDKGFYLDGSDTIVCDSNSTWDPVVPKCLKVLP 289  
HUNP\_758866.1 FPPVENGKQISGFGKKFYYKATVMFECDKGFYLDGSDTIVCDSNSTWDPVVPKCLKVVS-- 287  
HUNP\_758871.1 FPPVENGKQISGFGKKFYYKATVMFECDKGFYLDGSDTIVCDSNSTWDPVVPKCLK---- 285  
HUXP\_054192624.1 FPPVENGKQISGFGKKFYYKATVMFECDKGFYLDGSDTIVCDSNSTWDPVVPKCLK---- 285  
HUXP\_047276857.1 FPPVENGKQISGFGKKFYYKATVMFECDKGFYLDGSDTIVCDSNSTWDPVVPKCLKVSTS 289  
HUMNP\_758865.1 FPPVENGKQISGFGKKFYYKATVMFECDKGFYLDGSDTIVCDSNSTWDPVVPKCLKVSTS 289  
HUXP\_054192620.1 FPPVENGKQISGFGKKFYYKATVMFECDKGFYLDGSDTIVCDSNSTWDPVVPKCLKVLP 289  
HUXP\_047276850.1 FPPVENGKQISGFGKKFYYKATVMFECDKGFYLDGSDTIVCDSNSTWDPVVPKCLKVVS-- 287  
HUNP\_758867.1 FPPVENGKQISGFGKKFYYKATVMFECDKGFYLDGSDTIVCDSNSTWDPVVPKCLK---- 285  
:\*\*\* \*\*: :\*\*\*\*.\*\*\*\*\* \*:\*:\*: \*\* \*.\* \*\*\*\*\*.:\*\*\*\*.\* :\*:\*:\*

PIGXP\_020957856.1 TDPP--AT-----PGPSHPGPP-----SPSDASPPKD----AESLDGGIIAA 334  
PIGNP\_999053.1 TDPP--AT-----PGPSHPGPP-----SPSDASPPKD----AESLDGGIIAA 334  
PIGXP\_020957857.1 TDPP--AT-----PGPSHPGPP-----SPSDASPPKD----AESLDGGIIAA 334  
PIGXP\_020957858.1 TDPP--AT-----PGPSHPGPP-----SPSDASPPKD----AESLDGGIIAA 334  
HUNP\_758868.1 -----TSSTTKSPASSASGPRPTYKPPVSNYPGYPKPEEGILDSLVDVWVIAV 334  
HUNP\_758860.1 -----GPRPTYKPPVSNYPGYPKPEEGILDSLVDVWVIAV 319  
HUNP\_758863.1 T-----YKPPVSNYPGYPKPEEGILDSLVDVWVIAV 319  
HUXP\_054192621.1 SSTKPPALSHSVSTSS-----TKSPASSASGYPKPEEGILDSLVDVWVIAV 335  
HUNP\_758866.1 -----TSST-----TKSPASSASGYPKPEEGILDSLVDVWVIAV 320  
HUNP\_758871.1 -----GYPKPEEGILDSLVDVWVIAV 305  
HUXP\_054192624.1 -----GPRPTYKPPVSNYPGYPKPEEGILDSLVDVWVIAV 319  
HUXP\_047276857.1 STTKS-----PASSASGYPKPEEGILDSLVDVWVIAV 320  
HUMNP\_758865.1 STTKS-----PASSASGYPKPEEGILDSLVDVWVIAV 320  
HUXP\_054192620.1 SSTKPPALSHSVSTSSSTTKSPASSASGPRPTYKPPVSNYPGYPKPEEGILDSLVDVWVIAV 349  
HUXP\_047276850.1 -----TSSTTKSPASSASGPRPTYKPPVSNYPGYPKPEEGILDSLVDVWVIAV 334  
HUNP\_758867.1 -----GYPKPEEGILDSLVDVWVIAV 305  
. \*\* :\*\*\* :\*\*.

PIGXP\_020957856.1 IVVGVLAIAIAVIAGGVYFFHHKYNKKSLPVSVR-VLCWEWQCVSPSHSQQP-- 384  
PIGNP\_999053.1 IVVGVLAIAIAVIAGGVYFFHHKYNKKRSK----- 363  
PIGXP\_020957857.1 IVVGVLAIAIAVIAGGVYFFHHKYNKKRTEINASYSTYQDKAAAPAE----- 381  
PIGXP\_020957858.1 IVVGVLAIAIAVIAGGVYFFHHKYNKKRSK----- 363  
HUNP\_758868.1 IVIAIDIFKG-----GRRKKGQMVLELNPLTRL--NQPLQQSREAE 373  
HUNP\_758860.1 IVIAI-----GQMVLELNPLTRL--NQPLQQSREAE 349  
HUNP\_758863.1 IVIAIVVGVAVICVVPYRYLQRRKKKGKADGGAEYATYQTKSTTPAEQRG--- 369  
HUXP\_054192621.1 IVIAIVVGVAVICVVPYRYLQRRKKKGKADGGAEYATYQTKSTTPAEQRG--- 385  
HUNP\_758866.1 IVIAIVVGVAVICVVPYRYLQRRKKKGKADGGAEYATYQTKSTTPAEQRG--- 370  
HUNP\_758871.1 IVIAIVVGVAVICVVPYRYLQRRKKKGKADGGAEYATYQTKSTTPAEQRG--- 355  
HUXP\_054192624.1 IVIAIVVGVAVICVVPYRYLQRRKKKGTYLTDETHREVKFTSL----- 362  
HUXP\_047276857.1 IVIAIVVGVAVICVVPYRYLQRRKKKGTYLTDETHREVKFTSL----- 363  
HUMNP\_758865.1 IVIAIVVGVAVICVVPYRYLQRRKKKGTYLTDETHREVKFTSL----- 363  
HUXP\_054192620.1 IVIAIVVGVAVICVVPYRYLQRRKKKGTYLTDETHREVKFTSL----- 392  
HUXP\_047276850.1 IVIAIVVGVAVICVVPYRYLQRRKKKGTYLTDETHREVKFTSL----- 377  
HUNP\_758867.1 IVIAIVVGVAVICVVPYRYLQRRKKKGTYLTDETHREVKFTSL----- 348  
\*\*..:

Byrne\_Supplement\_2

CLUSTAL O(1.2.4) multiple sequence alignment
Annexin A2: Identity 97.94%

NP\_001005726.1 MSTVHEILCKLSLEGDHSTPASAYGSVKAYTNFDAERDALNIETAIKTKGVDEVTIVNIL 60
NP\_004030.1 MSTVHEILCKLSLEGDHSTPPSAYGSVKAYTNFDAERDALNIETAIKTKGVDEVTIVNIL 60
\*\*\*\*\*
NP\_001005726.1 TNRSNEQRQDIAFAYQRRTKKELASALKSALSGLHLETVILGGLKTPAQYDASELKASMKG 120
NP\_004030.1 TNRSNAQRQDIAFAYQRRTKKELASALKSALSGLHLETVILGGLKTPAQYDASELKASMKG 120
\*\*\*\*\*
NP\_001005726.1 LGTDEDSLIEIICSRTNQELQEINRVYKEMYKTDLKDIISDTSGDFRKLMLVALAKGRRA 180
NP\_004030.1 LGTDEDSLIEIICSRTNQELQEINRVYKEMYKTDLKDIISDTSGDFRKLMLVALAKGRRA 180
\*\*\*\*\*
NP\_001005726.1 EDGSVIDYELIDQDARDLYDAGVKKRGTDPVKWISIMTERSVCHLQKVFERYKSYSPYDM 240
NP\_004030.1 EDGSVIDYELIDQDARDLYDAGVKKRGTDPVKWISIMTERSVPHLQKVFDRYKSYSPYDM 240
\*\*\*\*\*
NP\_001005726.1 LESIKKEVKGDLEN AFLNLVQC IQNKPLYFADRLYDSMKGKGRDKVLIXIMVSRSEVDM 300
NP\_004030.1 LESIRKEVKGDLEN AFLNLVQC IQNKPLYFADRLYDSMKGKGRDKVLIRIMVSRSEVDM 300
\*\*\*\*\*
NP\_001005726.1 LKIRSEFKRKYGKSLYNYIQQDTKGDYQKALLYLCGGDD 339
NP\_004030.1 LKIRSEFKRKYGKSLYYYIQQDTKGDYQKALLYLCGGDD 339
\*\*\*\*\*

CLUSTAL O(1.2.4) multiple sequence alignment
CD9: Identity 90.18%

NP\_999171.1 MPVKGGTKCIKYLFGFNFIWLAGIAVLAIGLWLRFDSTQKSI FEQE--NNNSSFYTG 58
NP\_001400174.1 MPVKGGTKCIKYLFGFNFIWLAGIAVLAIGLWLRFDSTQKSI FEQETNNNSSFYTG 60
\*\*\*\*\*
NP\_999171.1 YILIGAGALMMVVGFLGCCGAVQESQCMLGLFFGFLVIFAIEIAAAIWGYSHKQVIKE 118
NP\_001400174.1 YILIGAGALMMLVVGFLGCCGAVQESQCMLGLFFGFLVIFAIEIAAAIWGYSHKDEVIKE 120
\*\*\*\*\*
NP\_999171.1 VQDFYRDTYNKLGKDDPQRET LKAIHYALDCCGLMGEVEQLLADICPQRDLVSSLMPKP 178
NP\_001400174.1 VQEFYKDTYNKLGKDEPQRET LKAIHYALNCCGLAGGVEQFISDICKPKDVLETF--TS 178
\*\*:\*:\*:\*\*\*\*\* \*\*:\*:\*\*\*\*\*:\*\*\*\* \* \*\*:::\*\*\*\*:\*\*\*.:
NP\_999171.1 CPEAIKEVFQNKFHII GAVGIGI AVVMIFGMIFSMILCCAIRSREMV 226
NP\_001400174.1 CPDAIKEVFDNKFHII GAVGIGI AVVMIFGMIFSMILCCAIRRNREMV 226
\*\*:\*:\*\*\*\*\*:\*\*\*\*\*:\*\*\*\*\*.\*

CLUSTAL O(1.2.4) multiple sequence alignment
CD59: Identity 47.54%

NP\_999335.1 MGSKGGFILLWLLSILAVLCHLGHSLQCYNCPNPTADCKTAVNCSDFDA CLITKA-GLQ 60
NP\_000602.1 MGIQGGSVLFGLLLVAVFCHSGHSLQCYNCPNPTADCKTAVNCSDFDA CLITKA-GLQ 59
\*\*:\*:\*: \*\*:\*:\*\*\*\*\* \*\*:\*:\*\*\*\*\* \*\*:\*:\*\*\*\*\* \*\*:\*:\*\*\*\*\*
NP\_999335.1 TYYQCFWFDECNFDFISRNLA EKKLKYNCCRKDLNCS DATISSGKT-----ALLVILL 114
NP\_000602.1 VYNKCKWFECNFNDVTRRLRENELTYCCCKDLNCFNEQLENGGTSLS EKTVLLLVTPF 119
.\*:\*:\*:\*\*\*: :.\*:\*:\*.\* \*\*:\*:\*\*\*\*\* .: .\*.: \*\*\*:
NP\_999335.1 LVATWHFCL 123
NP\_000602.1 LAAAWSLHP 128
\*.\*:\*:

CLUSTAL O(1.2.4) multiple sequence alignment

PROCR: Identity 70.59%

```
NP_001156878.1  MLTTLLPLLPLLLFPGRALCSQKVSDGPRDLRMLQVSYFRSPSQVWYQGNATLGGILTHV 60
NP_006395.2    ---MLTTLLPILLLSGWAFCSQDASDGLQRLHMLQISYFRDPYHVWYQGNASLGGHLTHV 57
                *  ***:*:* * *:***.*** : *:***:***.* :*****:*** **

NP_001156878.1  LEGPGHNVTIQQLQPLQEPESWELTKNSLEAYLKEFQGLVQVVHQERGVAFPLIVRCLLG 120
NP_006395.2    LEGPDTNTTIIQLQPLQEPESWARTQSGLSYLLQFHGLVRLVHQERTLAFPLTIRCFGL 117
                ****. *.** ***** *:.*:** :*:***:***** :**** :*:**

NP_001156878.1  CELPPEGSRARVFFEVAVNGSSFMSFQPETASWMARPQAASRVVTTYTVEQLNKYNRTRYE 180
NP_006395.2    CELPPEGSRAHVFFEVAVNGSSFVSRPERALWQADTQVTSGVVFTFLQQLNAYNRTRYE 177
                *****:*****:***:* * * * * .:* ***:*:*** *****

NP_001156878.1  LREFLQDTCVQYVQKHITHNKGSQTGRSYTPLVLGILVGCFFIAGVALCIFYVGGRR 240
NP_006395.2    LREFLEDTCVQYVQKHISAENTKGSQTSRSYTSLVLGVLVGSFFIAGVAVGIFLCTGGRR 237
                *****:*****:.* *****.*** ***:***.*****: *** .***

NP_001156878.1  RC 242
NP_006395.2    C- 238
```